Achillion Pharmaceuticals, Inc. (ACHN) Short Interest Down 18.3% in November
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) was the recipient of a large drop in short interest in November. As of November 30th, there was short interest totalling 7,056,852 shares, a drop of 18.3% from the November 15th total of 8,642,021 shares. Based on an average daily volume of 3,150,140 shares, the days-to-cover ratio is presently 2.2 days. Approximately 4.6% of the shares of the stock are sold short.
In other Achillion Pharmaceuticals news, major shareholder & Johnson Johnson sold 18,367,346 shares of the firm’s stock in a transaction on Monday, November 20th. The stock was sold at an average price of $2.75, for a total value of $50,510,201.50. The sale was disclosed in a filing with the SEC, which is available at this link. Company insiders own 7.24% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in ACHN. RTW Investments LP lifted its stake in shares of Achillion Pharmaceuticals by 392.9% in the 3rd quarter. RTW Investments LP now owns 7,839,766 shares of the biopharmaceutical company’s stock valued at $35,201,000 after acquiring an additional 6,249,312 shares during the last quarter. Janus Henderson Group PLC bought a new position in shares of Achillion Pharmaceuticals in the 2nd quarter valued at $20,778,000. Sarissa Capital Management LP bought a new position in shares of Achillion Pharmaceuticals in the 3rd quarter valued at $9,594,000. Dimensional Fund Advisors LP lifted its stake in shares of Achillion Pharmaceuticals by 75.3% in the 3rd quarter. Dimensional Fund Advisors LP now owns 3,276,076 shares of the biopharmaceutical company’s stock valued at $14,710,000 after acquiring an additional 1,407,108 shares during the last quarter. Finally, Senzar Asset Management LLC bought a new position in shares of Achillion Pharmaceuticals in the 2nd quarter valued at $4,966,000. Institutional investors own 76.93% of the company’s stock.
Achillion Pharmaceuticals (NASDAQ:ACHN) last announced its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.14) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.18) by $0.04. During the same period in the prior year, the firm earned ($0.15) earnings per share. sell-side analysts forecast that Achillion Pharmaceuticals will post -0.63 EPS for the current fiscal year.
A number of equities research analysts have weighed in on the company. Leerink Swann reaffirmed a “buy” rating and issued a $5.00 target price on shares of Achillion Pharmaceuticals in a report on Monday. Ladenburg Thalmann Financial Services reduced their target price on Achillion Pharmaceuticals from $9.00 to $6.50 and set a “buy” rating on the stock in a report on Tuesday, September 12th. Zacks Investment Research raised Achillion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.50 target price on the stock in a report on Monday, November 6th. Chardan Capital reaffirmed a “neutral” rating on shares of Achillion Pharmaceuticals in a report on Sunday, September 17th. Finally, Robert W. Baird reiterated a “neutral” rating and issued a $4.00 price target (down from $5.00) on shares of Achillion Pharmaceuticals in a research note on Tuesday, September 12th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $5.13.
About Achillion Pharmaceuticals
Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.
Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.